ANDA 78403, held by Granules. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 78403 (Sertraline Hydrochloride), held by Granules, was first approved by FDA on Jan 8, 2008, with 6 approved supplements and 0 published complete response letters.
Sertraline hydrochloride tablets are indicated for the treatment of the following:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 8, 2008 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sep 22, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 31, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 31, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 21, 2010 | Supplement 4Labeling | Approved | None posted |
| Sep 28, 2009 | Supplement 3Labeling | Approved | None posted |
| Apr 21, 2009 | Supplement 2Labeling | Approved | None posted |
| Jan 8, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters